226 related articles for article (PubMed ID: 30732646)
1. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation.
Lee SE; Lim JY; Kim TW; Ryu DB; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK
J Immunother Cancer; 2019 Feb; 7(1):35. PubMed ID: 30732646
[TBL] [Abstract][Full Text] [Related]
2. Graft monocytic myeloid-derived suppressor cell content predicts the risk of acute graft-versus-host disease after allogeneic transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood stem cells.
Vendramin A; Gimondi S; Bermema A; Longoni P; Rizzitano S; Corradini P; Carniti C
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2049-55. PubMed ID: 25246295
[TBL] [Abstract][Full Text] [Related]
3. Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma.
Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M
Exp Hematol; 2016 May; 44(5):342-351.e5. PubMed ID: 26774385
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients.
Jordan KR; Kapoor P; Spongberg E; Tobin RP; Gao D; Borges VF; McCarter MD
Cancer Immunol Immunother; 2017 Apr; 66(4):503-513. PubMed ID: 28108766
[TBL] [Abstract][Full Text] [Related]
5. Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation.
Tyrinova T; Batorov E; Aristova T; Ushakova G; Sizikova S; Denisova V; Chernykh E
Heliyon; 2024 Mar; 10(5):e26362. PubMed ID: 38434301
[TBL] [Abstract][Full Text] [Related]
6. The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever.
Rodríguez-Lobato LG; Martínez-Roca A; Castaño-Díez S; Palomino-Mosquera A; Gutiérrez-García G; Pedraza A; Suárez-Lledó M; Rovira M; Martínez C; Fernández de Larrea C; Cibeira MT; Rosiñol L; Lozano E; Marín P; Cid J; Lozano M; Moreno-Castaño AB; Palomo M; Díaz-Ricart M; Gallego C; Hernando A; Segura S; Carreras E; Urbano-Ispizua Á; Bladé J; Fernández-Avilés F
PLoS One; 2020; 15(11):e0241778. PubMed ID: 33147257
[TBL] [Abstract][Full Text] [Related]
7. Early Expansion of Circulating Granulocytic Myeloid-derived Suppressor Cells Predicts Development of Nosocomial Infections in Patients with Sepsis.
Uhel F; Azzaoui I; Grégoire M; Pangault C; Dulong J; Tadié JM; Gacouin A; Camus C; Cynober L; Fest T; Le Tulzo Y; Roussel M; Tarte K
Am J Respir Crit Care Med; 2017 Aug; 196(3):315-327. PubMed ID: 28146645
[TBL] [Abstract][Full Text] [Related]
8. Tumor-induced CD14+HLA-DR (-/low) myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients.
Wang Z; Zhang L; Wang H; Xiong S; Li Y; Tao Q; Xiao W; Qin H; Wang Y; Zhai Z
Cancer Immunol Immunother; 2015 Mar; 64(3):389-99. PubMed ID: 25548095
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
10. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL; Stadtmauer EA; Hwang WT; Lacey SF; Melenhorst JJ; Krevvata M; Carroll MP; Matsui WH; Wang Q; Dhodapkar MV; Dhodapkar K; Das R; Vogl DT; Weiss BM; Cohen AD; Mangan PA; Ayers EC; Nunez-Cruz S; Kulikovskaya I; Davis MM; Lamontagne A; Dengel K; Kerr ND; Young RM; Siegel DL; Levine BL; Milone MC; Maus MV; June CH
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669947
[TBL] [Abstract][Full Text] [Related]
11. Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma.
Favaloro J; Liyadipitiya T; Brown R; Yang S; Suen H; Woodland N; Nassif N; Hart D; Fromm P; Weatherburn C; Gibson J; Ho PJ; Joshua D
Leuk Lymphoma; 2014 Dec; 55(12):2893-900. PubMed ID: 24625328
[TBL] [Abstract][Full Text] [Related]
12. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
13. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.
Mougiakakos D; Jitschin R; von Bahr L; Poschke I; Gary R; Sundberg B; Gerbitz A; Ljungman P; Le Blanc K
Leukemia; 2013 Feb; 27(2):377-88. PubMed ID: 22828446
[TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
[TBL] [Abstract][Full Text] [Related]
16. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
17. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
18. Matrix Metalloproteinase-9 in Monocytic Myeloid-Derived Suppressor Cells Correlate with Early Infections and Clinical Outcomes in Allogeneic Hematopoietic Stem Cell Transplantation.
Lee SE; Lim JY; Kim TW; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min WS; Shin DM; Choi EY; Min CK
Biol Blood Marrow Transplant; 2018 Jan; 24(1):32-42. PubMed ID: 28844945
[TBL] [Abstract][Full Text] [Related]
19. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
Takamatsu H; Takezako N; Zheng J; Moorhead M; Carlton VEH; Kong KA; Murata R; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
Ann Oncol; 2017 Oct; 28(10):2503-2510. PubMed ID: 28945825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
